חוב לטווח קצר להון Abbott Laboratories (ABT)

Abbott Laboratories (ABT) demonstrates resilience driven by demand for consumables and glucose monitors, ensuring a stable cash flow. However, regulatory oversight and potential product recalls create operational risks. The strategy is based on the expansion of innovative medtech. This chart of the short-term debt-to-equity ratio confirms financial recovery, while 0.02 indicates the current leverage level.

This indicator measures the ability of equity to cover short-term debt obligations, assessing liquidity risk. By analyzing the historical ratio of short-term loans to equity, an investor determines the balance between financial stability and resource efficiency. Low values confirm protection against sudden shocks. For the diversified business of Abbott Laboratories (ABT) with its predictable cash flow, such stability guarantees margin resilience.